Propranolol given by intravenous pump to prevent pneumonia after bleeding in the brain
Tests propranolol by intravenous pump in people with bleeding in the brain.
Plain-language title generated from the registry record
Registry title: An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH
Key facts
- Where
- Xi'an, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults up to 80 years old who have a bleed inside the brain (intracerebral hemorrhage) and can start treatment within 24 hours. It tests propranolol by pump to prevent pneumonia after stroke.
- Age
- Older than 18 and up to 80 years.
- Sex
- All sexes can join.
- Disease stage
- Bleed in the upper part of the brain (supratentorial) of at least 10 mL. NIHSS score of 10 or more. GCS score of 6 or more. Treatment within 24 hours of the first symptoms.
- Earlier treatment
- No antibiotics in the last 2 weeks. No beta-blockers or reserpine in the last month.
Main reasons for not taking part
- Infection in the last 4 weeks, or fever or infection at admission
- Bleed in the brainstem or a bleed caused by injury, tumor, blood vessel defect or blood thinners
- Asthma or COPD, or serious heart problems such as heart failure, heart rate below 65 beats/min or heart block
- Pregnant or within 30 days of delivery
- Life expected to be less than 14 days
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 80 years old?
Source: NCT07528235, who can take part
Where in China
- Department of Neurosurgery , Tangdu Hospital, Fourth Military Medical UniversityXi'an, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tang-Du Hospital
- Trial code
- NCT07528235
- Record updated
- 14 April 2026
- Original description
This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.Read full original descriptionShow less
An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing Stroke-Associated Pneumonia of Intravenous Pump-Delivered Propranolol in Patients With Intracerebral Hemorrhage
This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.
Inclusion: Patients aged > 18 and ≤ 80 years of age; Can be treated with the study drug within 24 h of symptom onset; No fever or infection was observed upon admission; NIHSS score ≥10; Supratentorial parenchymal haematoma (≥10 mL); GCS score ≥ 6; Patients or their family members sign informed consent forms.
Exclusion: Previous disability with pre-ICH mRS score ≥ 2; Previous use (within 1 month) of β-blockers or reserpine; Infections within the last 4 weeks; Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes; Brainstem hemorrhage; Severe or acute heart failure; Heart rate < 65 beats/min; Known to be allergic to propranolol; Severe liver or renal insufficiency; History of malignant tumors; Use of antibiotics within the last 2 weeks; Known pre-ICH dysphagia; Life expectancy less than 14 days; Death appeared imminent; Pregnancy or within 30 d of delivery; Bronchial asthma or COPD; Cardiogenic shock; Degree II-III atrioventricular blocks; Currently participating in other interventional clinical trials; Currently, immunosuppressants and immunotherapies are being administered.